Literature DB >> 21933622

Increased expression of myocardial semaphorin 3A in isoproterenol-induced heart failure rats.

Shu-qin Sun1, Xin-tao Wang, Xiu-fen Qu, Yang Li, Yang Yu, Ying Song, Shao-jun Wang.   

Abstract

BACKGROUND: Maintenance of normal cardiac function is controlled by the autonomic nervous system. In congestive heart failure (CHF), sympathetic nerve denervation is increasingly recognized. The sympathetic fiber density depends on the balance between neurotrophins and neural guidance molecules. Semaphorin 3A (sema3a), a secreted neural guidance factor, is a well characterized member of the newly found semaphorin family. It can induce sympathetic growth cone collapse and axon repulsion. We conducted this study to investigate cell sources of sema3a in the heart, the expression level of sema3a in CHF and discuss the possible role of sema3a in CHF.
METHODS: Rats were divided into four groups: 30 days control group rats, 30 days CHF rats, 60 days control group rats, 60 days CHF rats. The heart failure model was induced by injection of isoproterenol (ISO) 340 mg/kg continuously two days. All animals underwent echocardiography and haemodynamics measurements. Cardiac expression of sema3a was determined by real time polymerase chain reaction (RT-PCR) and Western blotting analysis. Immunohistochemical analysis was used to determine the cell source of sema3a in the heart.
RESULTS: Isoproterenol induced 30 days and 60 days CHF rats displayed left ventricular dilation, systolic and diastolic function decrease. Sema3a was secreted by the cardiocytes and increased significantly in 30 days and 60 days CHF rats compared with the controls (RT-PCR: 30 days group: 0.32 ± 0.05 vs. 0.58 ± 0.06, P < 0.01; 60 days group: 0.34 ± 0.08 vs. 0.71 ± 0.07, P < 0.01. Western blotting: 30 days group: 0.25 ± 0.10 vs. 0.46 ± 0.10, P < 0.05; 60 days group: 0.29 ± 0.10 vs. 0.55 ± 0.16, P < 0.01. Immunohistochemical analysis: 30 days group: 2.91 ± 0.20 vs. 5.31 ± 0.30, P < 0.01; 60 days group: 2.94 ± 0.30 vs. 5.80 ± 0.30, P < 0.01).
CONCLUSIONS: Sema3a was expressed in the heart by cardiocytes. Increased expression of sema3a may partly account for sympathetic denervation in CHF; modulation of this pathway may prove beneficial in heart failure sympathetic remodeling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933622

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  4 in total

1.  Comparison of the effects of intramyocardial and intravenous injections of human mesenchymal stem cells on cardiac regeneration after heart failure.

Authors:  Behnaz Mokhtari; Nahid Aboutaleb; Donya Nazarinia; Mahin Nikougoftar; Seyed Mohammad Taghi Razavi Tousi; Mohammad Molazem; Mohammad-Reza Azadi
Journal:  Iran J Basic Med Sci       Date:  2020-07       Impact factor: 2.699

2.  β-adrenergic receptor-dependent alterations in murine cardiac transcript expression are differentially regulated by gefitinib in vivo.

Authors:  Jennifer A Talarico; Rhonda L Carter; Laurel A Grisanti; Justine E Yu; Ashley A Repas; Douglas G Tilley
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

3.  Semaphorin 3A attenuates cardiac autonomic disorders and reduces inducible ventricular arrhythmias in rats with experimental myocardial infarction.

Authors:  Hesheng Hu; Yongli Xuan; Mei Xue; Wenjuan Cheng; Ye Wang; Xinran Li; Jie Yin; Xiaolu Li; Na Yang; Yugen Shi; Suhua Yan
Journal:  BMC Cardiovasc Disord       Date:  2016-01-19       Impact factor: 2.298

4.  Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure?

Authors:  Nadav Willner; Yair Goldberg; Elad Schiff; Zahava Vadasz
Journal:  ESC Heart Fail       Date:  2018-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.